Oral hypoglycemic drugs

Reading File

Finding Sources

Reading File

Searching Images

oral hypoglycemic drugs mechanism of action diabetes

Finding Sources

Reading File

Searching Images

sulfonylurea meglitinide thiazolidinedione SGLT2 inhibitor DPP4 inhibitor antidiabetic drug classes comparison table

I have comprehensive content from Katzung's pharmacology textbook covering all major oral hypoglycemic drug classes. Now I'll compile a thorough, well-structured answer.

Oral Hypoglycemic Drugs

Oral hypoglycemic (antidiabetic) agents are used primarily for Type 2 Diabetes Mellitus. They work through distinct mechanisms targeting different aspects of glucose homeostasis. The major classes are outlined below.

1. Sulfonylureas

Mechanism

Sulfonylureas bind to a 140-kDa sulfonylurea receptor on pancreatic β-cells, closing ATP-sensitive K⁺ channels → membrane depolarization → Ca²⁺ influx → insulin exocytosis. They are insulin secretagogues (require functioning β-cells).

Generations & Agents

Generation	Drug	Dose	Half-life	Notes
1st	Tolbutamide	500 mg TID (max 3g/d)	4–5 h	Safe in elderly/renal impairment
1st	Chlorpropamide	100–500 mg/d	32 h	Avoid in elderly; SIADH risk
1st	Tolazamide	100–1000 mg/d	7 h	Slower absorption
2nd	Glipizide	5–40 mg/d	4 h	Lower hypoglycemia risk
2nd	Glyburide (glibenclamide)	1.25–20 mg/d	10 h	Hepatic + biliary excretion
2nd	Glimepiride	1–4 mg/d	5 h	Once daily; least hypoglycemia

Key Points

Risk of hypoglycemia is the primary adverse effect; especially with chlorpropamide and glyburide
Metabolized by liver; metabolites renally excreted
Second-generation agents have higher receptor affinity → lower doses → fewer drug interactions
Contraindicated in Type 1 DM, pregnancy, severe hepatic/renal disease
UKPDS confirmed no excess cardiovascular mortality with sulfonylureas

2. Meglitinides (Non-sulfonylurea Secretagogues)

Agents

Repaglinide (0.5–4 mg before meals)
Nateglinide (60–120 mg before meals)

Mechanism

Same receptor/channel as sulfonylureas but bind at a different site. Very rapid onset and short duration → reduce postprandial hyperglycemia. Must be taken with meals; skipping a meal = skip the dose.

Adverse Effects

Hypoglycemia (less than sulfonylureas); repaglinide metabolized entirely by liver (safe in renal impairment).

3. Biguanides — Metformin

Mechanism

Metformin's primary action: inhibits hepatic gluconeogenesis (reduces hepatic glucose output). Secondary: improves peripheral insulin sensitivity, reduces intestinal glucose absorption. Mechanism involves activation of AMP-activated protein kinase (AMPK) and inhibition of mitochondrial complex I.

Pharmacokinetics

Not metabolized; excreted unchanged by kidney
Half-life ~6 hours; 500–2550 mg/day in divided doses
No hypoglycemia (does not stimulate insulin secretion)
Weight-neutral or causes mild weight loss

Adverse Effects

GI: nausea, diarrhea, abdominal discomfort (start low, titrate up)
Lactic acidosis (rare but serious) — risk increases if renal/hepatic impairment, excessive alcohol, contrast media
Reduces vitamin B12 absorption (long-term use)

Contraindications

eGFR <30 mL/min/1.73 m² (avoid); reduce dose if eGFR 30–45
Hold before IV contrast dye
First-line agent for Type 2 DM per ADA/ACP guidelines

4. Thiazolidinediones (TZDs / Glitazones)

Agents

Pioglitazone (15–45 mg/day)
Rosiglitazone (4–8 mg/day; limited use due to CV concerns)

Mechanism

Bind PPARγ (peroxisome proliferator-activated receptor gamma) in adipose, muscle, and liver → increase insulin sensitivity, redistribute fat from visceral to subcutaneous, increase GLUT4 expression. They are insulin sensitizers — require insulin to work.

Key Points

Slow onset of full effect (6–12 weeks)
Cause fluid retention → edema, contraindicated in heart failure (NYHA Class III/IV)
Rosiglitazone: increased risk of MI (FDA black box warning; restricted use)
Pioglitazone: possible bladder cancer risk (long-term use); however, reduces cardiovascular events
Cause weight gain; bone fractures in women

5. Alpha-Glucosidase Inhibitors

Agents

Acarbose (25–100 mg TID with meals)
Miglitol (25–100 mg TID with meals)

Mechanism

Competitively inhibit intestinal α-glucosidase and pancreatic α-amylase enzymes → delay carbohydrate digestion and glucose absorption → blunt postprandial glucose spike.

Key Points

No hypoglycemia as monotherapy
GI side effects common: flatulence, bloating, diarrhea (fermentation of undigested carbs in colon)
If hypoglycemia occurs (e.g., combined with sulfonylurea), treat with glucose (not sucrose — sucrose absorption also blocked)
Modest HbA1c reduction (~0.5–0.8%)

6. DPP-4 Inhibitors (Gliptins)

Agents

Sitagliptin, saxagliptin, linagliptin, alogliptin, vildagliptin

Mechanism

Inhibit dipeptidyl peptidase-4 (DPP-4) → prevent degradation of endogenous GLP-1 and GIP → increased incretin levels → glucose-dependent insulin secretion + suppression of glucagon.

Key Points

Weight-neutral; low risk of hypoglycemia
HbA1c reduction: ~0.5–1.0%
Linagliptin: primarily biliary excretion — no dose adjustment in renal failure
Others: renal dose adjustment required
Adverse effects: nasopharyngitis, possible pancreatitis, joint pain (FDA warning)
Saxagliptin/alogliptin: slightly increased heart failure risk (post-marketing data)

7. SGLT2 Inhibitors (Gliflozins)

Agents

Empagliflozin, Dapagliflozin, Canagliflozin, Ertugliflozin

Mechanism

Block sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubule → prevent renal glucose reabsorption → glycosuria → lower plasma glucose. Also increase sodium excretion.

Key Points

Weight loss (caloric loss via urine) + BP reduction
Cardiovascular benefit: reduce mortality and hospitalization for heart failure — empagliflozin approved for HFrEF and HFpEF; dapagliflozin for HFrEF
Renoprotective: slow progression of diabetic kidney disease
Adverse effects: urinary tract infections, genital mycotic infections (glycosuria creates favorable environment), volume depletion, rare euglycemic diabetic ketoacidosis (in Type 1 or perioperative)
Do not initiate if eGFR <20 mL/min/1.73 m²; some agents require eGFR ≥45 for glucose-lowering efficacy

8. GLP-1 Receptor Agonists (Incretin Mimetics)

Strictly injectable, but oral semaglutide is now available:

Agents

Injectable: exenatide, liraglutide, dulaglutide, semaglutide (SC), albiglutide
Oral: semaglutide (Rybelsus)

Mechanism

Mimic GLP-1 → stimulate glucose-dependent insulin secretion, inhibit glucagon, slow gastric emptying, suppress appetite.

Key Points

Significant weight loss
Cardiovascular benefit: liraglutide and semaglutide reduce MACE (MI, stroke, CV death); approved for HFrEF
Adverse effects: nausea, vomiting (especially early); pancreatitis risk; contraindicated in personal/family history of MEN2 or medullary thyroid cancer
HbA1c reduction: 1.0–1.5%

Summary Table

Class	Mechanism	Hypoglycemia	Weight	Key Benefit	Key Risk
Sulfonylureas	↑ insulin secretion (K⁺ channel)	Yes	↑	Potent, inexpensive	Hypoglycemia
Meglitinides	↑ insulin secretion (postprandial)	Low	↑	Flexible dosing	Short duration
Metformin	↓ hepatic gluconeogenesis	No	↓/neutral	First-line, CVD neutral	Lactic acidosis (rare)
TZDs	PPARγ → ↑ insulin sensitivity	No	↑	Durable effect, pioglitazone CV+	Edema, fractures
α-Glucosidase inhibitors	Delay carb digestion	No	Neutral	Postprandial glucose	GI side effects
DPP-4 inhibitors	↑ incretin (GLP-1/GIP)	No	Neutral	Well tolerated	Nasopharyngitis
SGLT2 inhibitors	↑ glucosuria	No	↓	CV + renal protection	Genital infections, DKA
GLP-1 agonists (oral)	Incretin mimetic	No	↓↓	Weight loss, CV benefit	Nausea, pancreatitis

Treatment algorithm for glucose-lowering drugs in T2D, showing first-line role of metformin and SGLT2 inhibitors with renal function-based adjustments

Clinical Approach to Drug Selection

All patients: Metformin (first-line) + lifestyle modification
With ASCVD or high CV risk: Add GLP-1 RA (liraglutide, semaglutide) or SGLT2 inhibitor
With heart failure: Add SGLT2 inhibitor (empagliflozin/dapagliflozin)
With CKD: Add SGLT2 inhibitor (if eGFR ≥20) for renoprotection
Need to minimize hypoglycemia: DPP-4 inhibitors, GLP-1 RA, SGLT2i, TZDs
Need weight loss: GLP-1 RA or SGLT2 inhibitor
Cost-sensitive: Sulfonylureas or metformin (generic)

Sources: Katzung's Basic and Clinical Pharmacology, 16th Edition — Chapter 41; Goldman-Cecil Medicine, International Edition

This is a shared conversation. Sign in to Orris to start your own chat.